Search Results: Treatment + Pancreatic Cancer (6 results)
Treating Advanced Cancers with BRCA or Other Related Gene Mutations Using Targeted Therapy MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib
https://www.facingourrisk.org/research-clinical-trials/study/328/treating-advanced-cancers-with-dna-repair-mutations-using-moma-313-alone-or-in-combination-with-the-parp-inhibitor-olaparib
Treatment
Treatment study for people with advanced or metastatic cancers
This trial will study the safety, tolerability, and initial effectiveness of MOMA-313, a new type of targeted therapy, alone or in combination with the PARP inhibitor olaparib to treat people with advanced or metastatic cancers with certain types of mutations.
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/300/study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors
Treatment
Treatment study for people with advanced solid tumors
The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors. The study is enrolling people with BRCA1 or BRCA2 inherited mutations and have HER2-negative breast cancer, prostate cancer, pancreatic cancer, high grade ovarian, fallopian tube or primary peritoneal cancer; or other solid tumors with certain genetic mutations.
Treating Advanced or Metastatic Cancers with a New PARP1 Inhibitor (GS-0201) Alone or Combined with Other Drugs
https://www.facingourrisk.org/research-clinical-trials/study/350/treating-advanced-or-metastatic-cancers-with-the-new-parp-inhibitor-alone-or-combined-with-other-drugs
Treatment
Treatment study for people with advanced or metastatic solid tumors
The goal of this treatment study is to learn if the new drug GS-0201 is safe and can help treat people with different types of metastatic or advanced cancer. GS-0201 is a new drug that has not yet been approved for treatment of cancer. GS-0201 is a type of targeted therapy known as a PARP1 inhibitor.
Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)
https://www.facingourrisk.org/research-clinical-trials/study/282/study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
This research involves studying a drug called AZD9574 on its own and in combination with other anti-cancer drugs in people with advanced cancer that has come back or progressed. AZD9574 is a type of targeted therapy known as a PARP inhibitor. The study aims to understand the safety, tolerance, how the drug moves in the body, how it affects the body, and its initial effectiveness.
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib
Treatment
Treatment study for people with advanced solid tumors
This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.
Treating Metastatic Breast or Pancreatic Cancer in People with an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Stem Cells
https://www.facingourrisk.org/research-clinical-trials/study/117/sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells
Treatment
Treatment study for metastatic breast or pancreatic cancer in people with an inherited BRCA1 or BRCA2 mutation
The purpose of this study is to see whether the combination of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer or Stage IV, HER2-negative breast cancer who have a BRCA1, BRCA2 or PALB2 inherited mutation. All of these treatments are given intravenously (by vein). This study is open to people who have already received a PARP inhibitor, as well as those who have not. There are no restrictions on the number of prior treatments a patient has received before enrolling.
Additional Results on Clinicaltrials.gov Treatment + Pancreatic Cancer + PARP
4 results
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
NCT ID: NCT04858334 (https://clinicaltrials.gov/study/NCT04858334)
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT ID: NCT04550494 (https://clinicaltrials.gov/study/NCT04550494)
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
NCT ID: NCT05411094 (https://clinicaltrials.gov/study/NCT05411094)
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
NCT ID: NCT04005690 (https://clinicaltrials.gov/study/NCT04005690)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.